XFOR — X4 Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $97.40m
- $71.36m
Annual cashflow statement for X4 Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -52.8 | -62.1 | -88.7 | -93.9 | -101 |
| Depreciation | |||||
| Non-Cash Items | 7.88 | 7.03 | 18.8 | 10.5 | 3.89 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.24 | -4.06 | -1.5 | 5.74 | 0.344 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -48.1 | -58.8 | -70.9 | -77.1 | -96.5 |
| Capital Expenditures | -0.174 | -1.36 | -0.615 | -0.103 | -0.06 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 27.4 | 0 | 0 | — | -14.8 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Cash from Investing Activities | 27.2 | -1.36 | -0.615 | -0.103 | -14.9 |
| Financing Cash Flow Items | — | -0.278 | 0 | -4.81 | -0.631 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 141 | 12.4 | 74.2 | 117 | 88.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 120 | -47.4 | 2.41 | 39.9 | -22.8 |